Related Experiment Video

Updated: Oct 16, 2026

Rapid Depletion of Renal Macrophages Using Human CD59/Intermedilysin Cell Ablation Tool
10:15

Rapid Depletion of Renal Macrophages Using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

Decline of met-enkephalins concentration after interleukin-2 subcutaneous administration due to renal carcinoma

B Zubelewicz1, R Braczkowski, W Romanowski

  • 15th Dept. of Internal Medicine, Silesian Medical University, Zeromskiego, Bytom, Poland.

Journal of Experimental & Clinical Cancer Research : CR
|June 7, 2000
PubMed

Insights

Interleukin-2 (IL-2) administration in renal cancer patients significantly decreases Met-Enkephalins (Met-Enk) serum levels. This finding highlights the intricate link between the immune and nervous systems.

Area of Science:

  • Neuroimmunology
  • Oncology
  • Endocrinology

Background:

  • The nervous and immune systems exhibit complex bidirectional communication pathways.
  • Endogenous opioids, such as Met-Enkephalins, are key mediators in neuro-immune interactions.
  • Cytokines, like Interleukin-2 (IL-2), can modulate the endogenous opioid system.

Purpose of the Study:

  • To investigate the effect of subcutaneous Interleukin-2 (IL-2) administration on serum Met-Enkephalin (Met-Enk) concentrations.
  • To assess this neuro-immune interaction in the context of renal cancer treatment.

Main Methods:

  • Single subcutaneous administration of IL-2 to renal cancer patients.
  • Quantification of serum Met-Enk levels using the Radioimmunoassay (RIA) method.

Main Results:

  • A single administration of IL-2 led to a statistically significant reduction in serum Met-Enk levels.
  • This demonstrates a measurable impact of immunotherapy on endogenous opioid concentrations.

Conclusions:

  • Subcutaneous IL-2 administration significantly impacts the endogenous opioid system in renal cancer patients.
  • These findings underscore the neuro-immune modulation occurring during IL-2 therapy.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...